Adirondack Trust Co. lessened its position in shares of Celgene Co. (NASDAQ:CELG) by 7.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,386 shares of the biopharmaceutical company’s stock after selling 105 shares during the period. Adirondack Trust Co.’s holdings in Celgene were worth $137,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently modified their holdings of the company. Anderson Hoagland & Co. lifted its holdings in shares of Celgene by 48.0% during the 3rd quarter. Anderson Hoagland & Co. now owns 18,610 shares of the biopharmaceutical company’s stock worth $1,801,000 after acquiring an additional 6,034 shares during the period. Havens Advisors LLC increased its position in Celgene by 12.8% during the 3rd quarter. Havens Advisors LLC now owns 146,600 shares of the biopharmaceutical company’s stock worth $14,557,000 after purchasing an additional 16,600 shares in the last quarter. Northwest Bancshares Inc. increased its position in Celgene by 2.1% during the 3rd quarter. Northwest Bancshares Inc. now owns 30,635 shares of the biopharmaceutical company’s stock worth $3,042,000 after purchasing an additional 642 shares in the last quarter. Gulf International Bank UK Ltd increased its position in Celgene by 0.6% during the 3rd quarter. Gulf International Bank UK Ltd now owns 169,283 shares of the biopharmaceutical company’s stock worth $16,809,000 after purchasing an additional 962 shares in the last quarter. Finally, Wiley BROS. Aintree Capital LLC increased its position in Celgene by 7.5% during the 3rd quarter. Wiley BROS. Aintree Capital LLC now owns 3,095 shares of the biopharmaceutical company’s stock worth $277,000 after purchasing an additional 215 shares in the last quarter. 72.41% of the stock is owned by institutional investors.

In other Celgene news, insider Terrie Curran sold 11,338 shares of the company’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $98.27, for a total value of $1,114,185.26. Following the completion of the transaction, the insider now directly owns 13,493 shares in the company, valued at approximately $1,325,957.11. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.39% of the company’s stock.

NASDAQ CELG traded up $0.75 on Wednesday, hitting $99.63. The company’s stock had a trading volume of 2,281,157 shares, compared to its average volume of 7,062,730. The company has a quick ratio of 3.32, a current ratio of 3.44 and a debt-to-equity ratio of 1.97. Celgene Co. has a 1-year low of $58.59 and a 1-year high of $100.42. The company’s 50-day moving average is $97.87 and its 200 day moving average is $94.97. The firm has a market cap of $70.66 billion, a PE ratio of 13.09, a PEG ratio of 0.51 and a beta of 1.42.

Celgene (NASDAQ:CELG) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $2.61 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.44 by $0.17. Celgene had a net margin of 32.24% and a return on equity of 89.93%. The firm had revenue of $4.40 billion during the quarter, compared to analysts’ expectations of $4.22 billion. During the same period in the prior year, the company posted $2.16 EPS. The company’s revenue was up 15.4% on a year-over-year basis. On average, equities analysts expect that Celgene Co. will post 9.96 EPS for the current year.

CELG has been the subject of a number of research analyst reports. ValuEngine cut shares of Celgene from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 1st. Mizuho cut shares of Celgene from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $103.00 to $100.00 in a research report on Monday, August 19th. Zacks Investment Research upgraded shares of Celgene from a “sell” rating to a “hold” rating and set a $94.00 price objective for the company in a research report on Tuesday, July 23rd. BidaskClub upgraded shares of Celgene from a “hold” rating to a “buy” rating in a research report on Tuesday, October 1st. Finally, Cowen reiterated a “hold” rating and set a $102.00 price objective on shares of Celgene in a research report on Tuesday, July 30th. One equities research analyst has rated the stock with a sell rating, seventeen have given a hold rating and four have given a buy rating to the stock. Celgene currently has a consensus rating of “Hold” and an average target price of $94.60.

Celgene Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Featured Story: Arbitrage

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.